Possible scenario
Pipeline Gap Narrows
40% Chance
Investors view the $2.6 billion Hengrui license as a credible step toward rebuilding Novo Nordisk's oral obesity pipeline after concerns highlighted in 2025 and 2026. The deal does not immediately displace Eli Lilly's oral GLP-1 lead, but it reduces the perceived risk that Novo falls behind in next-generation obesity formats.
Secondary impacts
- Healthcare +0.3%
Tickers
- LLY-1.0%
Portfolio impact
S&P 500+0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.